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retained in the 96-well plate via magnetic separation using the mag-
netic bed. The 384-well plate was read in the Erenna system to count 
individual Alexa Fluor dye-labelled detection antibody molecules from 
each well. The limit of detection for this ET-1 assay was 0.07 pg/mL 
and the lower limit of quantification was 0.175 pg/mL. Intra-assay pre-
cision (20 replicates) was 3% at 11.4 pg/mL, and interassay precision 
(five assay runs) was 7% at 7.8 pg/mL. This assay measures the active 
form of ET-1. In testing to assess ET-1 sample integrity in human 
plasma, ET-1 showed no signal loss after 9 months of storage at −70 
∘C. Freeze–thaw testing revealed no signal loss after seven cycles. Our 
samples were thawed only once previously for aliquoting from original 
tubes and shipping. All ET-1 measurements were performed in 2014. 
NT-proBNP levels were determined by the clinically available 
VITROS® NT-proBNP Assay (Ortho-Clinical Diagnostics, Raritan, NJ, 
USA).
Clinical endpoints
The composite of death or recurrent heart failure hospitalization 
within 30 days of randomization was a primary endpoint in the over-
all ASCEND-HF trial. Death and worsening heart failure were assessed 
together as a composite secondary endpoint and all events were adjudi-
cated to 180 days. In this biomarker substudy, we analysed the following 
adjudicated outcomes: death at 30 days; death or rehospitalization at 
30 days; death at 180 days; and death or worsening heart failure prior 
to discharge (Supplementary material online, Table S1).
Statistical analyses
Baseline characteristics were presented as median [interquartile range 
(IQR)] for continuous variables and as a percentage for categori-
cal variables. The Jonckheere–Terpstra and Cochran–Armitage trend 
tests were used to assess the significance of a trend across increas-
ing tertiles of ET-1 for continuous and categorical variables, respec-
tively. Two-sided P-values <0.05 were considered statistically signifi-
cant. ET-1 levels were not normally distributed, and therefore were 
expressed as log-transformed. Baseline and follow-up ET-1 levels were 
compared between patients randomly assigned to placebo or nesiri-
tide via the Wilcoxon rank sum test. The association between con-
tinuous, log-transformed ET-1 and intermediate outcomes was per-
formed via logistic regression analyses for in-hospital death or wors-
ening heart failure. The association between log-transformed ET-1 
and long-term outcomes was performed via Cox proportional haz-
ards models for the endpoints of 30-day mortality, 180-day mortality, 
in-hospital death or worsening heart failure, and 30-day mortality or 
rehospitalization. For multivariable analyses, hazard ratios (HRs) and 
odds ratios (ORs) were adjusted for covariates that were previously 
identified for the overall ASCEND-HF study population (ASCEND-HF 
risk model, Supplementary material online, Table S1). Age, systolic 
blood pressure <140 mmHg, and blood urea nitrogen (BUN) were 
used as covariates in multivariable analyses assessing possible asso-
ciations between ET-1 and 180-day mortality. To assess if the addi-
tion of ET-1 to the ASCEND-HF risk model improves outcome pre-
diction, we calculated the area under the receiver operating char-
acteristic curve (AUC), integrated discrimination improvement (IDI), 
and category-free net reclassification improvement (NRI). NT-proBNP, 
cystatin C, hsCRP, and cTnI were also included as additional covari-
ates in secondary multivariable analyses. The Kaplan–Meier method 
was used to compare 180-day mortality across groups. Statistical 
analyses were performed using R software (Version 3.1.2, Vienna, 
Austria).
levels, correlates with clinical severity,1,4,5 and is associated with 
mortality.6 –8 Understanding changes in ET-1 during acute decom-
pensated heart failure (ADHF) may help identify a subgroup of 
patients who are high risk for adverse clinical outcomes. Further-
more, it is possible that this high risk subgroup may benefit from 
therapies that interfere with ET-1 production or signalling, includ-
ing relaxin receptor agonists.9 In the hope of further exploring 
some of these possibilities, we examined the relationship of base-
line and serial ET-1 measurements with mortality, worsening heart 
failure, and rehospitalization in hospitalized patients with ADHF 
who were part of the Acute Study of Clinical Effectiveness of Nesir-
itide in Decompensated Heart Failure (ASCEND-HF) biomarker 
substudy. In this observational, hypothesis-generating analysis, we 
also assessed ET-1’s potential prognostic role in relation to acute 
heart failure biomarkers, including NT-proBNP.
Methods
Study population
The ASCEND-HF trial was a multicentre randomized double-blind 
placebo-controlled trial that evaluated the effects of nesiritide, a 
recombinant BNP and vasodilator, in patients hospitalized with ADHF. 
We excluded patients with clinical evidence of acute coronary syn-
drome or baseline cardiac troponin >5 times the upper reference limit, 
as measured by the local clinical laboratory. The design and primary 
results of ASCEND-HF have been previously reported.10,11 Studies 
assessing cardiac troponin I (cTnI), high-sensitivity C-reactive protein 
(hsCRP), and cystatin C in acute heart failure using subcohorts from 
ASCEND-HF have been previously published.12 –14 Out of 7411 patients 
randomized in ASCEND-HF, our biomarker study enrolled 872 patients 
in whom ET-1 was measured from serial venous blood sampling at 
baseline, 48–72 h after therapy initiation, and at a 30-day follow-up visit. 
Blood samples were collected in EDTA-plasma between June 2008 and 
September 2010. They were immediately centrifuged and stored at −80 
∘C for subsequent analysis at a core laboratory.
Endothelin-1 measurement
Circulating plasma ET-1 levels were measured from plasma samples 
taken at baseline (n = 872), 48–72 h (n = 691), and 30 days (n = 643). 
Measurements were performed using the Erenna® Immunoassay Sys-tem 
(Singulex, Inc., Alameda, CA, USA), which is based upon single molecule 
counting technology.15 Specifically, 100 𝜇L of assay buffer with 
paramagnetic microparticles (1 μm, Dynabeads® MyOne™, Life 
Technologies) coated with capture antibody (MAB3440, R&D Systems, 
Minneapolis, MN, USA) were added to each well in a 96-well plate; 100 
𝜇L assay samples were added to each well in the plate. The plate was 
covered and incubated for 2 h at 25 ∘C. The plate was then washed to 
remove unbound material, and a magnetic bed (Ambion) was used to 
retain the microparticles in the well. Then, 20 𝜇L of detection antibody 
(MA3005, R&D Systems) with Alexa Fluor® label were added to each 
well. The plate was covered and incubated for 1 h at 25 ∘C and  washed. 
The magnetic bed was used to retain microparticles in the well, and was 
transferred to a fresh 96-well plate, and the bound detection antibody 
was released from the microparticles via elution with 10 𝜇L of glycine. 
Glycine buffer, containing Alexa Fluor dye-labelled detection antibody 
(MA3005, R&D Systems), was transferred to a 384-well receptacle plate 
containing 10 𝜇L of 0.5 M Tris buffer. The microparticles were






